LeMaitre Vascular (LeMaitre Vascular) Cash, Cash Equivalents, Marketable Securities : $105.1 Mil (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is LeMaitre Vascular Cash, Cash Equivalents, Marketable Securities?

LeMaitre Vascular's quarterly cash, cash equivalents, marketable securities increased from Jun. 2023 ($90.18 Mil) to Sep. 2023 ($97.02 Mil) and increased from Sep. 2023 ($97.02 Mil) to Dec. 2023 ($105.07 Mil).

LeMaitre Vascular's annual cash, cash equivalents, marketable securities increased from Dec. 2021 ($69.96 Mil) to Dec. 2022 ($82.69 Mil) and increased from Dec. 2022 ($82.69 Mil) to Dec. 2023 ($105.07 Mil).

LeMaitre Vascular Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for LeMaitre Vascular's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LeMaitre Vascular Cash, Cash Equivalents, Marketable Securities Chart

LeMaitre Vascular Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

32.68

26.98

69.96

82.69

105.07

LeMaitre Vascular Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															82.69	81.01	90.18	97.02	105.07

LeMaitre Vascular Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

LeMaitre Vascular (NAS:LMAT) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

LeMaitre Vascular Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of LeMaitre Vascular's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

LeMaitre Vascular (LeMaitre Vascular) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LeMaitre Vascular Inc (NAS:LMAT) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

LHU:Germany

Address

63 Second Avenue, Burlington, MA, USA, 01803

Website

https://www.lemaitre.com

LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are primarily used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes the largest proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.

Executives

George W Lemaitre	director, 10 percent owner, officer: Chairman, President and CEO	342 BUNKER HILL STREET, #2B, CHARLESTOWN MA 02129
Bridget A Ross	director	C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
John A Roush	director	C/O GSI GROUP INC., 125 MIDDLESEX TURNPIKE, BEDFORD MA 01730-1409
Lawrence J Jasinski	director	SOTEIRA INC., 14 TECH CIRCLE, NATICK MA 01760
David B Roberts	director, officer: CFO and Director	55 BRADFORD STREET, NEEDHAM MA 02492
Trent G Kamke	officer: Senior V. P., Operations	61 WILLOWDEAN AVENUE, WEST ROXBURY MA 02132
Martha Shadan	director	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Pellegrino Joseph P Jr	officer: Executive V.P. Finance	68 BEACON STREET, BOSTON MA 02108
Michael H Thomas	director	P.O. BOX 2207, NOKOMIS FL 34274-2207
Peter R Gebauer	officer: President, International OP	AM WALDFELD 17, BAD SODEN 2M 65812
Michael T Wijas	officer: VP of Sales, The Americas	C/O LEMAITRE VASCULAR, INC., 63 SECOND AVENUE, BURLINGTON MA 01803
Lemaitre Cornelia W	director, officer: V.P., Human Resources,Director	8 SUNSET ROCK ROAD, ANDOVER MA 01810
Russell D Hays	director	C/O BIOSOURCE INTERNATIONAL INC, 542 FLYNN RD, CAMARILLO CA 93012
Robert V Linden	officer: VP, North American Sales	236 WOODEN BRIDGE ROAD, HOLLAND PA 18966
Thorndike William N Jr	director	HOUSATONIC PARTNERS, 800 BOYLSTON STREET, SUITE 2220, BOSTON MA 02199